Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India

The editorial discusses the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with diabetic nephropathy and their underutilization in government hospitals in India for the treatment of diabetic nephropathy. The authors provide a comprehensive analysis of various fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Maradia, Jay, Joshi, Shirish S, Sohal, Amitoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243670/
https://www.ncbi.nlm.nih.gov/pubmed/37288210
http://dx.doi.org/10.7759/cureus.38676
_version_ 1785054473288155136
author Maradia, Jay
Joshi, Shirish S
Sohal, Amitoj
author_facet Maradia, Jay
Joshi, Shirish S
Sohal, Amitoj
author_sort Maradia, Jay
collection PubMed
description The editorial discusses the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with diabetic nephropathy and their underutilization in government hospitals in India for the treatment of diabetic nephropathy. The authors provide a comprehensive analysis of various factors contributing to the under-prescription of these medications, including lack of awareness and education among healthcare professionals, limited availability and accessibility of medications, high cost, and poor adherence to evidence-based guidelines. Addressing these factors through education, research, and affordable pricing and reimbursement policies may help improve the appropriate prescription of SGLT-2 inhibitors in government hospitals in India.
format Online
Article
Text
id pubmed-10243670
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-102436702023-06-07 Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India Maradia, Jay Joshi, Shirish S Sohal, Amitoj Cureus Endocrinology/Diabetes/Metabolism The editorial discusses the beneficial effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with diabetic nephropathy and their underutilization in government hospitals in India for the treatment of diabetic nephropathy. The authors provide a comprehensive analysis of various factors contributing to the under-prescription of these medications, including lack of awareness and education among healthcare professionals, limited availability and accessibility of medications, high cost, and poor adherence to evidence-based guidelines. Addressing these factors through education, research, and affordable pricing and reimbursement policies may help improve the appropriate prescription of SGLT-2 inhibitors in government hospitals in India. Cureus 2023-05-07 /pmc/articles/PMC10243670/ /pubmed/37288210 http://dx.doi.org/10.7759/cureus.38676 Text en Copyright © 2023, Maradia et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Maradia, Jay
Joshi, Shirish S
Sohal, Amitoj
Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
title Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
title_full Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
title_fullStr Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
title_full_unstemmed Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
title_short Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
title_sort underutilization of sodium-glucose cotransporter 2 (sglt-2) inhibitors in diabetic nephropathy patients in government-run hospitals in india
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243670/
https://www.ncbi.nlm.nih.gov/pubmed/37288210
http://dx.doi.org/10.7759/cureus.38676
work_keys_str_mv AT maradiajay underutilizationofsodiumglucosecotransporter2sglt2inhibitorsindiabeticnephropathypatientsingovernmentrunhospitalsinindia
AT joshishirishs underutilizationofsodiumglucosecotransporter2sglt2inhibitorsindiabeticnephropathypatientsingovernmentrunhospitalsinindia
AT sohalamitoj underutilizationofsodiumglucosecotransporter2sglt2inhibitorsindiabeticnephropathypatientsingovernmentrunhospitalsinindia

Ejemplares similares